Trial Profile
A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin From Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox) Using Focused Ultrasound in Patients With Primary or Secondary Liver Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Cholangiocarcinoma; Liver cancer; Liver metastases
- Focus First in man; Pharmacokinetics; Proof of concept
- Acronyms TARDOX
- 19 Sep 2022 According to an Imunon media release, Celsion Corporation changed it's name to Imunon.
- 17 Jan 2019 Results presented in a Celsion Corporation media release.
- 17 Jan 2019 According to a Celsion Corporation media release, the results from this study were published in the peer-reviewed journal, Radiology.